Related Experiment Video
Updated: Jun 19, 2026
12:00
Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles
Published on: January 22, 2015
12.3K
Development and Characterization of Lyophilized Chondroitin Sulfate-Loaded Solid Lipid Nanoparticles: Encapsulation
Marta E Bustos Araya1, Anna Nardi Ricart2, Ana C Calpena Campmany2,3
1Instituto de Investigaciones Farmacéuticas, Facultad de Farmacia, Universidad de Costa Rica, San José 11501, Costa Rica.
Pharmaceutics
|January 25, 2025
Summary
Lyophilized chondroitin sulfate (CHON)-loaded solid lipid nanoparticles (SLN) were developed for enhanced drug delivery. The optimized SLN-2 formulation demonstrated superior stability and high encapsulation efficiency, showing potential for treating inflammatory diseases.
Area of Science:
- Nanotechnology
- Materials Science
- Pharmacology
Background:
- Solid lipid nanoparticles (SLN) offer biocompatibility and enhanced drug stability, bioavailability, and efficacy.
- Chondroitin sulfate (CHON), a glycosaminoglycan, possesses anti-inflammatory and regenerative properties.
- Advanced drug delivery systems are crucial for treating inflammatory and degenerative diseases.
Purpose of the Study:
- To develop and characterize lyophilized chondroitin sulfate (CHON)-loaded solid lipid nanoparticles (SLN).
- To optimize SLN formulations for enhanced drug delivery and stability.
- To evaluate the potential of CHON-loaded SLNs for therapeutic applications.
Main Methods:
- Chondroitin sulfate (CHON) was encapsulated into SLN using the hot microemulsion technique.
- Formulations were optimized by assessing particle size, zeta potential, encapsulation efficiency (EE%), and stability.
- Lyophilization was performed with cryoprotectants, identifying trehalose as optimal; characterization included TEM, AFM, DSC, and XRD.
Main Results:
- Transmission electron microscopy (TEM) and atomic force microscopy (AFM) confirmed nanoscale dimensions and uniformity.
- Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) indicated minimal excipient-CHON interaction, ensuring stability.
- The SLN-2 formulation exhibited the highest stability, with encapsulation efficiency ≥88% and consistent particle size over time.
Conclusions:
- Lyophilized CHON-loaded SLNs represent a promising platform for advanced drug delivery.
- The SLN-2 formulation demonstrates significant potential for targeted, sustained-release therapies.
- These nanoparticles show promise for the treatment of inflammatory and degenerative diseases.
